表紙
市場調査レポート

膵外分泌機能不全:パイプライン分析

Exocrine Pancreatic Insufficiency - Pipeline Review, H2 2015

発行 Global Markets Direct 商品コード 293887
出版日 ページ情報 英文 47 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.32円で換算しております。
Back to Top
膵外分泌機能不全:パイプライン分析 Exocrine Pancreatic Insufficiency - Pipeline Review, H2 2015
出版日: 2015年09月09日 ページ情報: 英文 47 Pages
概要

膵外分泌機能不全(EPI)は膵外分泌酵素の欠乏を特徴とする疾患で、消化不良を引き起こします。下痢、軟便、脂肪分が吸収されない脂肪便、ビタミン欠乏、食欲不振、原因不明の体重減少といった症状があります。治療には、膵酵素補充療法(PERT)、生活習慣の改善などがあります。

当レポートでは、世界における膵外分泌機能不全治療薬のパイプライン製品について取り上げ、現在の開発パイプラインの状況や最新動向、後期段階および中止されたプロジェクトの情報、主要企業および彼らが開発中の製品のレビューなどをお届けします。

イントロダクション

  • 調査範囲

膵外分泌機能不全の概要

治療薬の開発

  • パイプライン製品の概要
  • パイプライン製品の比較分析

膵外分泌機能不全:開発中の治療薬:企業別

膵外分泌機能不全:パイプライン製品の概況

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品

膵外分泌機能不全:開発中の製品:企業別

膵外分泌機能不全:治療薬開発に従事している企業

  • Allergan Plc
  • Anthera Pharmaceuticals, Inc.
  • Cilian AG
  • Laboratoires Mayoly Spindler S.A.S.
  • Nordmark Arzneimittel GmbH & Co. KG

膵外分泌機能不全:治療薬の評価

  • 単剤製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

  • burlulipase
  • Cilase
  • リプロタマーゼ
  • MS-1819
  • パンクレリパーゼDR
    • 製品概要
    • 作用機序
    • R&Dの進捗

膵外分泌機能不全:最近のパイプライン動向

膵外分泌機能不全:休止中のプロジェクト

膵外分泌機能不全:中止プロジェクト

膵外分泌機能不全:製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7157IDB

Summary

Global Markets Direct's, 'Exocrine Pancreatic Insufficiency - Pipeline Review, H2 2015', provides an overview of the Exocrine Pancreatic Insufficiency's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Exocrine Pancreatic Insufficiency, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Exocrine Pancreatic Insufficiency and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Exocrine Pancreatic Insufficiency
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Exocrine Pancreatic Insufficiency and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Exocrine Pancreatic Insufficiency products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Exocrine Pancreatic Insufficiency pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Exocrine Pancreatic Insufficiency
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Exocrine Pancreatic Insufficiency pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Exocrine Pancreatic Insufficiency Overview
  • Therapeutics Development
    • Pipeline Products for Exocrine Pancreatic Insufficiency - Overview
    • Pipeline Products for Exocrine Pancreatic Insufficiency - Comparative Analysis
  • Exocrine Pancreatic Insufficiency - Therapeutics under Development by Companies
  • Exocrine Pancreatic Insufficiency - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Exocrine Pancreatic Insufficiency - Products under Development by Companies
  • Exocrine Pancreatic Insufficiency - Companies Involved in Therapeutics Development
    • Allergan Plc
    • Anthera Pharmaceuticals, Inc.
    • Cilian AG
    • Laboratoires Mayoly Spindler S.A.S.
    • Nordmark Arzneimittel GmbH & Co. KG
  • Exocrine Pancreatic Insufficiency - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • burlulipase - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Cilase - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • liprotamase - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MS-1819 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • pancrelipase DR - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Exocrine Pancreatic Insufficiency - Recent Pipeline Updates
  • Exocrine Pancreatic Insufficiency - Dormant Projects
  • Exocrine Pancreatic Insufficiency - Discontinued Products
  • Exocrine Pancreatic Insufficiency - Product Development Milestones
    • Featured News & Press Releases
      • Mar 19, 2015: Anthera Announces $3 Million Research Award from Cystic Fibrosis Foundation Therapeutics for Development of Sollpura - a Novel Enzyme Therapy
      • Nov 20, 2014: Anthera and Patheon Sign Manufacturing Agreement for Liprotamase Phase III Registration Trial
      • Dec 10, 2012: Aptalis Pharma Announces US Commercial Availability Of Ultresa Delayed-release Capsules
      • Aug 01, 2012: Cilian Receives €1m Grant For Development Of Cilase
      • Mar 01, 2012: Aptalis Pharma Receives FDA Approval For ULTRESA Pancrelipase Delayed Release Capsules
      • Jul 14, 2011: Aptalis Pharma Receives FDA Approval Of 25,000 Lipase-Unit Strength Of ZENPEP
      • Jun 17, 2011: Aptalis Pharma Receives FDA Approval For New Low Strength Of ZENPEP
      • Apr 15, 2011: Lilly Receives Complete Response Letter From FDA For Liprotamase For Treatment Of Exocrine Pancreatic Insufficiency
      • Feb 11, 2011: Axcan Completes Acquisition of Eurand and Commences Subsequent Offering Period
      • Jan 12, 2011: Lilly Announces FDA Panel Recommendation For Liprotamase
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Exocrine Pancreatic Insufficiency, H2 2015
  • Number of Products under Development for Exocrine Pancreatic Insufficiency - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Comparative Analysis by Late Stage Development, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Development, H2 2015
  • Products under Development by Companies, H2 2015
  • Exocrine Pancreatic Insufficiency - Pipeline by Allergan Plc, H2 2015
  • Exocrine Pancreatic Insufficiency - Pipeline by Anthera Pharmaceuticals, Inc., H2 2015
  • Exocrine Pancreatic Insufficiency - Pipeline by Cilian AG, H2 2015
  • Exocrine Pancreatic Insufficiency - Pipeline by Laboratoires Mayoly Spindler S.A.S., H2 2015
  • Exocrine Pancreatic Insufficiency - Pipeline by Nordmark Arzneimittel GmbH & Co. KG, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Stage and Target, H2 2015
  • Number of Products by Stage and Mechanism of Action, H2 2015
  • Number of Products by Stage and Route of Administration, H2 2015
  • Number of Products by Stage and Molecule Type, H2 2015
  • Exocrine Pancreatic Insufficiency Therapeutics - Recent Pipeline Updates, H2 2015
  • Exocrine Pancreatic Insufficiency - Dormant Projects, H2 2015
  • Exocrine Pancreatic Insufficiency - Discontinued Products, H2 2015

List of Figures

  • Number of Products under Development for Exocrine Pancreatic Insufficiency, H2 2015
  • Number of Products under Development for Exocrine Pancreatic Insufficiency - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Top 10 Targets, H2 2015
  • Number of Products by Stage and Top 10 Targets, H2 2015
  • Number of Products by Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2015
  • Number of Products by Top 10 Molecule Types, H2 2015
  • Number of Products by Stage and Top 10 Molecule Types, H2 2015
Back to Top